Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis (Q52141693)

23 April 2018

title

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis (English)

1 reference

23 April 2018

0 references

5

1 reference

23 April 2018

Tomáš Kalinčík

11

1 reference

23 April 2018

Dana Horáková

12

1 reference

23 April 2018

Lukáš Sobíšek

object named as

Lukas Sobisek

4

0 references

Eva Havrdová

object named as

Eva Havrdova

10

0 references

Robert Zivadinov

9

object named as

Robert Zivadinov

1 reference

23 April 2018

Tomas Uher

1

1 reference

23 April 2018

Tomas Uher

2

1 reference

23 April 2018

Manuela Vaneckova

3

1 reference

23 April 2018

Zdenek Seidl

6

1 reference

23 April 2018

Jan Krasensky

7

1 reference

23 April 2018

Deepa Ramasamy

8

1 reference

23 April 2018

publication date

6 April 2016

1 reference

23 April 2018

Multiple Sclerosis Journal

published in

1 reference

23 April 2018

volume

23

1 reference

23 April 2018

issue

1

1 reference

23 April 2018

page(s)

51-61

1 reference

23 April 2018

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study

cites work

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Assessing treatment response to interferon-β: is there a role for MRI?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Scoring treatment response in patients with relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Callosal lesion predicts future attacks after clinically isolated syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Brain atrophy and lesion load predict long term disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Association between MRI parameters and the MS severity scale: a 12 year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Predictive value of early brain atrophy on response in patients treated with interferon β

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Gray matter damage predicts the accumulation of disability 13 years later in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Thalamic damage and long-term progression of disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Thalamic atrophy is associated with development of clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Early predictors of non-response to interferon in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Axonal Transection in the Lesions of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

Measures in the first year of therapy predict the response to interferon β in MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458516642314

21 January 2018

Identifiers

DOI

10.1177/1352458516642314

1 reference

23 April 2018

1 reference

23 April 2018